The Vascular Surgeon's Role in Risk Factor Modification: Results of a Survey

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 17, Issue 2, 2005, Pages 145-153

  Leon, Luis R ^a   Labropoulos, Nicos ^a   Lebda, Paulette ^a   Kalman, Peter G ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

peripheral arterial disease; risk factor management; vascular surgeons

Indexed keywords

ARTERIOSCLEROSIS; ARTICLE; CLINICAL PRACTICE; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; RISK FACTOR; RISK REDUCTION; SURGERY; VASCULAR SURGERY;

ARTERIOSCLEROSIS; ATTITUDE OF HEALTH PERSONNEL; DATA COLLECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SPECIALTIES, SURGICAL; VASCULAR SURGICAL PROCEDURES;

EID: 33644697087     PISSN: 15310035     EISSN: None     Source Type: Journal    
DOI: 10.1177/153100350501700220     Document Type: Article

References (48)

1. Criqui MH. Peripheral arterial disease-epidemiological aspects. Vasc Med 6:3-7, 2001.
2. Kalman P.G., Irvine J, Ritvo P. How do vascular surgeons perceive atherosclerotic risk factor management? Ann Vasc Surg 14:652-658, 2000.
3. Rastel D, Perrin M. Guidicell H. Compressive therapy after varicose vein surgery: results of a French national inquiry. Mal Vasc 29:27-34, 2004.
4. Pillny M, Luther B, Muller B.T., Sandmann W. Survey of therapy of deep venous thrombosis among members of the German Society of Vascular Surgery. Chirurg 73:180-184, 2002.
5. McDermott M.M., Greenland P, Hahn E.A., et al. The effects of continuing medical education credits on physician response rates to a mailed questionnaire. Health Mark Q 20:27-42, 2003.
6. Caprini J.A., Arcelus J.I., Hoffman K, et al. Prevention of venous thromboembolism in North America: results of a survey among general surgeons. J Vasc Surg 20:751-758, 1994.
7. Wijesinghe L.D., Gamage L, Berridge D.C., Scott DJ. Measuring serum total cholesterol: do vascular surgeons know what they are doing? Ann R Coll Surg Engl 81:32-36, 1999.
8. Basnyat P.S., Moseley L.G., al-Rawi M. et al. Smoking do vascular surgeons practise what they preach? Ann R Coll Surg EngI 82:424-427, 2000.
9. Leung G.M., Ho L.M., Chan M.F., et al. The effects of cash and lottery incentives on mailed surveys to physicians: a randomized trial. J Clin Epidemiol 55:801-807, 2002.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000.
11. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002.
12. Henke P.K., Blackburn S, Proctor M.C., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39:357-365, 2004.
13. Hirsch A.T., Criqui M.H., Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286:1317-1324, 2001.
14. Stewart CP. The influence of smoking on the level of Iower limb amputation. Prosthet Orthot Int 11:113-116, 1987.
15. Hirsch A.T., Treat-Jacobson D, Lando H.A., et al. The role of tobacco cessation, antiplatelet and lipid-low-ering therapies in the treatment of peripheral arterial disease. Vasc Med 2:243-251, 1997.
16. Valentine R.J., Guerra R, Stephan P, et al. Family history is a major determinant of subclinical peripheral arterial disease in young adults. J Vasc Surg 39:351-356, 2004.
17. Anda R.F., Remington P.L., Sienko D.G., Davis RM. Are physicians advising smokers to quit? The patient's perspective. JAMA 257:1916-1919, 1987.
18. Viswesvaran C, Schmidt FL. A meta-analytic comparison of the effectiveness of smoking cessation methods. J Appl Psychol 77:554-561, 1992.
19. Bains N, Pickett W. Hoey J. The use and impact of incentives in population-based smoking cessation programs: a review. Am J Health Promot 12:307-320, 1998.
20. Saltzhbeg S.S., Pomposelli FB Jr, Belfield A.K., et al. Outcome of lower-extremity revascularization in patients younger than 40 years in a predominantly diabetic population. J Vasc Surg 38:1056-1059, 2003.
21. Lawler F.H., Viviani N. Patient and physician perspectives regarding treatment of diabetes: compliance with practice guidelines. J Fam Pract 44:369-373, 1997.
22. Stokes J 3rd, Kannel W.B., Wolf P.A., et al. The relative importance of selected risk factors for various marifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow up in the Framingham Study. Circulation 75:V65-V73, 1987.
23. Mann K.V., Putnam RW. Physicians perceptions of their role in cardiovascular risk ieduction. Piev Med 18:45-58, 1989.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
25. Anand S.S., Kundi A, Eikelboom J, Yusuf S. Low rates of preventative practices in patients with peripheral vascular disease. Can J Cardiol 15:1259-1263, 1999.
26. Jovin I.S., Muller-Berghaus G. Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis. Atherosclerosis 174:225-233, 2004.
27. Pekkanen J, Linn S. Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322: 1700-1707, 1990.
28. Mittelmark M.B., Leupker R.V., Grimm R Jr, et al. The role of physicians in a community-wide program for prevention of cardiovascular disease: The Minnesota Heart Health Program. Public Health Rep 103:360-365, 1988.
29. Pynn M, Schafer K, Konstantinides S, Halle M. Exercise training reduces neointimal growth and stabilizes vascular lesions developing after injury in apolipoprotein e-deficient mice. Circulation 109:386-392, 2004.
30. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109:220-226, 2004.
31. Carnethon M.R., Gidding S.S., Nehgme R, et al. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease RFs. JAMA 290:3092-3100, 2003.
32. Latikkanen J.A., Lakka T.A., Rauramaa R. et al. Cardiovascular fitness as a predictor of mortality in men Arch Intern Med 161:825-831, 2001.
33. Perkins J.M., Collin J, Creasy T.S., et al. Exercise training versus angioplasty for stable claudication I ong and medium term results of a prospective, randomised trial. Eur J Vasc Enodovasc Surg 11:409-413, 1996.
34. Church T.S., Kampert J.B., Gibbons L.W., et al. Usefulness of cardiorespiratory fitness as a predictor of all cause and cardiovascular disease mortality in men with systemic hypertension. Am J Cardiol 88:651-656, 2001.
35. Gardner A.W., Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 274:975-980, 1995.
36. Mora S, Redberg R.F., Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women. A 20-year follow-up of the Lipid Research Clinics Prevalence Study. JAMA 290:1600-1607, 2003.
37. Patterson R.B., Pinto B, Marcus B, et al. Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg 25:312-318, 1997.
38. Savage P Ricci M.A., Lynn M, et al. Effects of home versus supervised exercise for patients with intermittent claudication. J CardiopUlm Rehabil 21:152-157, 2001.
39. Cheetham D.R., Burgess L, Ellis M, et al. Does supervised exercise offer adjuvant benefit over exercise advice alone for the treatment of intermittent claudication? A randomised trial. Eur J Vasc Endovasc Surg 27:17-23, 2004.
40. Egede L.E., Zheng D. Modifiable cardiovascular RFs in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med 162:427-433, 2002.
41. Silagy C, Muir J, Thorogood M, Roe L. Cardio-vascular risk and attitudes to lifestyle: what do patients think? BMJ 306:1657-1660, 1993.
42. Dietz WH Jr., Gortmaker SL. Factors within the physical environment associated with childhood obesity. Am J Clin Nutr 39:619-624, 1984.
43. Ogden C.L., Flegal K.M., Carroll M.D., Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288:1728-1732, 2002.
44. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/Anmericani Heart Association conference on scientific issues related to definition. Circulation 109:43-48, 2004.
45. Tavlor LM Jr. Elevated plasma homocysteine as risk factor for peripheral arterial disease-what is the evidence? Semin Vasc Surg 16:215-222, 2003.
46. SkIbinska E, Sawicki R, Lewczuk A, et al. Homocysteine and progression of coronary artery disease. Kardiol Pol 60:197-205, 2004.
47. Taylor LM Jr., Moneta G.L., Sexton G.J., et al. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29:8-21, 1999.
48. Lentzner B.J., Connolly D.M., Phoon CK. Do paediatric cardiologists discuss cardiovascular RFs with patients and their families? Cardiol Young 13:551-558, 2003.